Company
Merck
Merck has 120 drugs tracked on RxWires: 8 post-market, 4 approved, 37 in Phase 3, 2 in Phase 2/3, 29 in Phase 2, 9 in Phase 1/2, 31 in Phase 1.
- Ticker
- MRK
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Rebif® | Post-Market | Multiple Sclerosis, Relapsing-Remitting |
| Crinone | Post-Market | Infertility |
| Gonal-f | Post-Market | Infertility |
| Fidaxomicin | Post-Market | Clostridium Difficile Infection (CDI) |
| elbasvir, grazoprevir | Post-Market | Chronic Hepatitis C |
| Gabapentin/B-complex | Post-Market | Diabetic Peripheral Neuropathic Pain |
| Interferon beta-1a (Rebif) | Post-Market | Multiple Sclerosis, Relapsing-Remitting |
| Nirogacestat | Post-Market | Desmoid Tumor |
| RECARBRIO | Approved | |
| LIPFENDRA | Approved | |
| TIMOLIDE 10-25 | Approved | |
| BELSOMRA | Approved | |
| Intismeran | Phase 3 | Non-small Cell Lung Cancer |
| Intismeran autogene | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis |
| Pergoveris® | Phase 3 | Infertility |
| Follitropin alfa/lutropin alfa (MBJ-0011) | Phase 3 | Infertility |
| Sacituzumab Tirumotecan | Phase 3 | Cervical Cancer |
| Sac-TMT | Phase 3 | Bladder Cancer |
| Belzutifan | Phase 3 | Carcinoma, Renal Cell |
| Ensifentrine | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| Molnupiravir | Phase 3 | Coronavirus Disease (COVID-19) |
| Nemtabrutinib | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell |
| blood sampling | Phase 3 | Infertility, Female |
| MK0767 | Phase 3 | Diabetes Mellitus, Type 2 |
| Gardasil™ | Phase 3 | Papillomavirus Infections |
| Pembrolizumab | Phase 3 | Bladder Cancer |
| Tedizolid phosphate | Phase 3 | Acute Bacterial Skin and Skin Structure Infections |
| Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) | Phase 3 | Reproductive Techniques, Assisted |
| Patritumab deruxtecan | Phase 3 | Breast Neoplasms |
| R-DXd | Phase 3 | Ovarian Cancer |
| Gocatamig | Phase 3 | Small Cell Lung Cancer |
| Ifinatamab deruxtecan | Phase 3 | Prostate Cancer |
| VARIVAX™ New Seed Process | Phase 3 | Varicella |
| Lenvatinib | Phase 3 | Carcinoma, Hepatocellular |
| Comparator: sitagliptin 100 mg | Phase 3 | Diabetes Mellitus, Type 2 |
| Cladribine Low Dose | Phase 3 | Generalized Myasthenia Gravis |
| Posaconazole | Phase 3 | Aspergillosis |
| Etoricoxib 60 mg | Phase 3 | Soft Tissue Injuries of the Shoulder |
| Cetuximab | Phase 3 | Carcinoma, Squamous Cell of Head and Neck |
| budesonide | Phase 3 | Asthma |
| favezelimab/pembrolizumab | Phase 3 | Colorectal Cancer |
| Calderasib | Phase 3 | Non-small Cell Lung Cancer |
| V181 | Phase 3 | |
| SC Tulisokibart | Phase 3 | Crohn's Disease |
| Ipragliflozin | Phase 3 | Type 2 Diabetes Mellitus |
| Bomedemstat | Phase 3 | Thrombocythemia, Essential |
| Zilovertamab vedotin | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Ensifentrine 3 mg twice daily | Phase 3 | COPD |
| Vericiguat tablet | Phase 2/3 | Heart Failure |
| MK-1045 | Phase 2/3 | B-cell Acute Lymphoblastic Leukemia |
| Raludotatug Deruxtecan | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| MK-6916 | Phase 2 | Pain Management |
| Part A: RPL554 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| MK0457 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Vicriviroc maleate | Phase 2 | HIV |
| RPL554 Suspension | Phase 2 | COPD |
| Arm A: Pemetrexed Cisplatin | Phase 2 | Non Small Cell Lung Cancer |
| Pimicotinib | Phase 2 | Tenosynovial Giant Cell Tumor |
| M5049 low dose | Phase 2 | Systemic Lupus Erythematosus |
| Mirdametinib (PD-0325901) oral capsule or dispersible tablet | Phase 2 | Plexiform Neurofibroma |
| Salbutamol | Phase 2 | Chronic Obstructive Pulmonary Disease |
| Glycopyrrolate (85 μg) | Phase 2 | Chronic Obstructive Pulmonary Disease |
| Minocycline | Phase 2 | Multiple Sclerosis, Relapsing-Remitting |
| DPX-Survivac | Phase 2 | Ovarian Cancer |
| Islatravir | Phase 2 | Human Immunodeficiency Virus |
| MK-1942 | Phase 2 | Treatment Resistant Depression |
| Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium | Phase 2 | COPD |
| SCH 727965 | Phase 2 | Breast Neoplasms |
| V212 | Phase 2 | Herpes Zoster |
| Donepezil | Phase 2 | Alzheimer's Disease |
| Ibutamoren Mesylate (MK-0677) | Phase 2 | Fibromyalgia |
| Posaconazole IV 6 mg/kg | Phase 2 | Invasive Fungal Infection |
| alvimopan | Phase 2 | Cancer |
| MK-6096 | Phase 2 | Diabetic Neuropathy, Painful |
| Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) | Phase 2 | Ebola Virus Disease |
| r-hFSH | Phase 2 | Infertility |
| Nebulized Ensifentrine Suspension; 3 mg | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
| 1.5 mg RPL554 plus tiotropium | Phase 2 | Chronic Obstructive Pulmonary Disease Moderate |
| MK-1084 | Phase 2 | Malignant Neoplasm |
| MK2461 | Phase 1/2 | Neoplasm |
| Tepotinib | Phase 1/2 | Carcinoma, Hepatocellular |
| Docetaxel | Phase 1/2 | Castration-Resistant Prostatic Cancer |
| Mirdametinib | Phase 1/2 | NF1 |
| Fulvestrant | Phase 1/2 | Breast Cancer |
| Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) | Phase 1/2 | Infertility Implantation Failure |
| Opevesostat | Phase 1/2 | Prostatic Neoplasms, Castration-Resistant |
| MK-3120 | Phase 1/2 | Advanced Solid Tumors |
| I-DXd | Phase 1/2 | Oesophageal Squamous Cell Carcinoma |
| Pergoveris FD | Phase 1 | Healthy |
| Peposertib | Phase 1 | |
| V175 | Phase 1 | Lower Respiratory Tract Infection |
| MK-0616A | Phase 1 | |
| MK-4002 | Phase 1 | Multiple Myeloma in Relapse |
| Metformin/Gliclazide Fixed Combination | Phase 1 | Healthy |
| MK-8245 | Phase 1 | Type 2 Diabetes Mellitus |
| MK1006 | Phase 1 | Type 2 Diabetes Mellitus |
| [14C]Berzosertib | Phase 1 | Advanced Solid Tumor |
| Evobrutinib | Phase 1 | Healthy |
| Reference Eutirox® | Phase 1 | Healthy |
Latest
- Zilovertamab Vedotin moved to Phase 3
- Bomedemstat moved to Phase 3
- Tulisokibart moved to Phase 3
- Opevesostat moved to Phase 1/2
- merck filed 8-K
Follow Merck on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.